Suisse - français - Swissmedic (Swiss Agency for Therapeutic Products)

novartis pharma schweiz ag - ofatumumabum - solution injectable en seringue préremplie - ofatumumabum 20 mg, argininum, natrii acetas trihydricus, natrii chloridum, polysorbatum 80, dinatrii edetas, acidum hydrochloridum 25 per centum, aqua ad iniectabile q.s. ad solutionem pro 0.4 ml corresp. natrium 0.92 mg. - multiple sklerose - biotechnologika

Suisse - français - Swissmedic (Swiss Agency for Therapeutic Products)

novartis pharma schweiz ag - ofatumumabum - solution injectable en stylo prérempli - ofatumumabum 20 mg, argininum, natrii acetas trihydricus, natrii chloridum, polysorbatum 80, dinatrii edetas, acidum hydrochloridum 25 per centum, aqua ad iniectabile q.s. ad solutionem pro 0.4 ml corresp. natrium 0.92 mg. - multiple sklerose - biotechnologika

Canada - français - Health Canada

novartis pharmaceuticals canada inc - ofatumumab - solution - 20mg - ofatumumab 20mg - immunomodulatory agents

Union européenne - français - EMA (European Medicines Agency)

novartis ireland ltd - ofatumumab - la sclérose en plaques, sep récurrente-rémittente - immunosuppressant - kesimpta is indicated for the treatment of adult patients with relapsing forms of multiple sclerosis (rms) with active disease defined by clinical or imaging features (see section 5.